Opportunities for general internal medicine to promote equity in obesity care
If appetite suppression and weight loss progress well at a given dose, there may be no need to increase further
Bringing up the topic with your provider doesnt have to be uncomfortable
Liraglutide (Saxenda) was one of the earlier forms of longer-lasting GLP-1s and reduces HbA1c (average blood glucose) levels by around 1.3% on average and fasting plasma glucose by 2 mmol/L
Safety Monitoring To ensure safe escalation, clinical protocols monitored: Liver enzymes (ALT, AST) Kidney function Cardiovascular markers (blood pressure, lipids) Blood glucose in diabetic and non-diabetic participants So far, no significant cardiovascular safety issues have been reported, though long-term Phase 3 data will be critical before final conclusions can be made
UK patients should understand that: Available evidence is largely from Phase 2 studies with relatively short follow-up periods Long-term cardiovascular outcome data are not yet available for either agent Phase 3 trials are ongoing, and results will inform future regulatory submissions to the MHRA UK patients interested in accessing these treatments through clinical trials may wish to consult the NIHR 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk) or ClinicalTrials.gov for current recruitment opportunities
.webp)
